Lund, June 12, Hamlet Pharma, ticker HAMLET, soon to be Hamlet BioPharma, the innovative pharmaceutical company with a strong portfolio of projects for the treatment of cancer and infections, announces that Hamlet Pharma has extended and expanded the agreement with the Swiss public company Polypeptide Group, ticker PPGN, to produce larger quantities of the synthetic peptide Alpha1. The new production, at a larger scale, will be essential for future expansions of the clinical trial program in bladder cancer.
BLACKROCK GREATER EUROPE INVESTMENT TRUST PLC
LEI: 5493003R8FJ6I76ZUW55
Half yearly financial announcement of results in respect of the six months ended 28 February 2023
PERFORMANCE. | May 10, 2023
PolyPeptide Group / Key word: Partnership
PolyPeptide and Numaferm announce partnership to leverage their expertise for the more sustainable production of peptide-based APIs. | May 9, 2023